Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073539 | 0.87 | VDR (0.45) | NPC1VDRALDH1A1KDM4EMAPT | |
| SCHEMBL31174248 | 0.84 | VDR (0.48) | NPC1VDRALDH1A1KDM4EHSD17B10 | |
| SCHEMBL900164 | 0.84 | VDR (0.48) | NPC1VDRALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31174250 | 0.84 | VDR (0.48) | NPC1VDRALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3311841 | 0.81 | MAPT (0.41) | NPC1VDRMAPT | |
| SCHEMBL19857729 | 0.79 | TSHR (0.44) | NPC1NLRP3TLR8P2RX3KDM4E | |
| SCHEMBL5951467 | 0.79 | NPC1 (0.41) | NPC1NLRP3TLR8P2RX3JAK2 | |
| SCHEMBL5953236 | 0.76 | NPC1 (0.39) | NPC1NLRP3TLR8P2RX3JAK2 | |
| SCHEMBL5952387 | 0.75 | TLR8 (0.42) | NPC1NLRP3TLR8P2RX3JAK2 | |
| SCHEMBL23932593 | 0.74 | VDR (0.35) | NPC1VDRALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | NPC1 2673/4885NLRP3 2850/4885TLR8 4353/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | NPC1 2673/4885NLRP3 2850/4885TLR8 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.